Viking Therapeutics reported earnings of -$ 1.55 per VKTX share on Oct 28, 2026, beating analysts' expectations by
| Report Date | Oct 28, 2026 |
|---|---|
| Forecasted EPS | -$ 1.06 |
| Earnings Per Share (Surprise) | -$ 1.55 (-$ 0.49) |
| Last Year's EPS | -$ 0.79 |
| EPS YoY Change |
Out of the last 56 earnings reporting periods, Viking Therapeutics beat analysts’ expectations 20 times and fell short of expectations 24 time(s). Viking Therapeutics reported earnings per share of -$ 1.55 in the last report falling to reach an estimated EPS of -$ 1.06 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Oct 28, 2026 | -$ 1.06 | -$ 1.55 | -$ 0.81 | |
| Jul 29, 2026 | -$ 1.23 | -$ 1.10 | -$ 0.58 | |
| Apr 29, 2026 | -$ 1.01 | -$ 1.37 | -$ 0.41 | |
| Feb 11, 2026 | -$ 0.89 | -$ 1.38 | -$ 0.32 | |
| Oct 22, 2025 | -$ 0.70 | -$ 0.81 | -$ 0.22 | |
| Jul 23, 2025 | -$ 0.44 | -$ 0.58 | -$ 0.20 | |
| Apr 23, 2025 | -$ 0.34 | -$ 0.41 | -$ 0.26 | |
| Feb 5, 2025 | -$ 0.28 | -$ 0.32 | -$ 0.25 | |
| Oct 23, 2024 | -$ 0.24 | -$ 0.22 | -$ 0.23 | |
| Jul 24, 2024 | -$ 0.26 | -$ 0.20 | -$ 0.19 | |
| Apr 24, 2024 | -$ 0.27 | -$ 0.26 | -$ 0.25 | |
| Feb 7, 2024 | -$ 0.25 | -$ 0.25 | -$ 0.26 | |
| Oct 25, 2023 | -$ 0.22 | -$ 0.23 | -$ 0.21 | |
| Jul 26, 2023 | -$ 0.21 | -$ 0.19 | -$ 0.23 | |
| Apr 26, 2023 | -$ 0.24 | -$ 0.25 | -$ 0.21 | |
| Feb 8, 2023 | -$ 0.23 | -$ 0.26 | -$ 0.16 | |
| Oct 26, 2022 | -$ 0.23 | -$ 0.21 | -$ 0.17 | |
| Jul 27, 2022 | -$ 0.21 | -$ 0.23 | -$ 0.20 | |
| Apr 27, 2022 | -$ 0.20 | -$ 0.21 | -$ 0.19 | |
| Feb 9, 2022 | -$ 0.19 | -$ 0.16 | -$ 0.15 |
Viking Therapeutics’s stock was trading at $ 24.89 on Oct 27, 2026 a day before the last earnings report was released.Following the release of the earnings report, VKTX’s price increased to $ 26.86 on Oct 29, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Oct 28, 2026 | -$ 1.55 | $ 24.89 | $ 26.86 | |
| Jul 29, 2026 | -$ 1.10 | $ 33.86 | $ 33.11 | |
| Apr 29, 2026 | -$ 1.37 | $ 32.39 | $ 31.18 | |
| Feb 11, 2026 | -$ 1.38 | $ 28.75 | $ 30.49 | |
| Oct 22, 2025 | -$ 0.81 | $ 32.98 | $ 33.92 | |
| Jul 23, 2025 | -$ 0.58 | $ 32.10 | $ 33.50 | |
| Apr 23, 2025 | -$ 0.41 | $ 25.48 | $ 25.66 | |
| Feb 5, 2025 | -$ 0.32 | $ 32.37 | $ 31.46 | |
| Oct 23, 2024 | -$ 0.22 | $ 62.03 | $ 73.22 | |
| Jul 24, 2024 | -$ 0.20 | $ 51.54 | $ 64.68 | |
| Apr 24, 2024 | -$ 0.26 | $ 64.93 | $ 68.86 | |
| Feb 7, 2024 | -$ 0.25 | $ 24.61 | $ 28.89 | |
| Oct 25, 2023 | -$ 0.23 | $ 10.65 | $ 9.67 | |
| Jul 26, 2023 | -$ 0.19 | $ 14.49 | $ 13.71 | |
| Apr 26, 2023 | -$ 0.25 | $ 19.88 | $ 19.61 | |
| Feb 8, 2023 | -$ 0.26 | $ 9.96 | $ 10.68 | |
| Oct 26, 2022 | -$ 0.21 | $ 4.09 | $ 4.03 | |
| Jul 27, 2022 | -$ 0.23 | $ 3.26 | $ 3.19 | |
| Apr 27, 2022 | -$ 0.21 | $ 2.29 | $ 2.42 | |
| Feb 9, 2022 | -$ 0.16 | $ 3.59 | $ 4.05 |
Viking Therapeutics released its most recent earnings reports in October 2026, July 2026, April 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Viking Therapeutics missed analysts’ expectations during the last earnings period by
